Clinical trial · Interventional
Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Several cytotoxic regimens are related to endothelial cell damage and vascular toxicity. Endothelial dysfunction is implicated in the pathogenesis of all known cardiovascular diseases (CVD) and closely related to the metabolic syndrome. Both CVD and diabetes contributes importantly to total mortality and to breast cancer (BC) specific mortality. In the epidemiological part of the project, the investigators will determine the prevalence and incidence of cardiovascular and metabolic morbidity/mortality in early BC patients compared to the Danish background population. In the clinical part, the investigators will study the changes of endothelial function and metabolic parameters in BC patients receiving chemotherapy. With increasing number of BC survivors, long-term consequences of curative cancer treatment should be studied. The investigators hypothesize that cytotoxic therapy worsens metabolic parameters possibly through endothelial dysfunction. If this is true, the next step will be to evaluate how strict metabolic control will affect prognosis.
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Neoplasms | Breast Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Cardiovascular Disease | — | UNRESOLVED | — |
| Endothelial Dysfunction | — | UNRESOLVED | — |
| Metabolic Syndrome | — | UNRESOLVED | — |
Interventions
Interventions (5)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 24hour blood pressure | Procedure | — | UNRESOLVED |
| DEXA scan | Procedure | — | UNRESOLVED |
| Laboratory blood samples | Biological | — | UNRESOLVED |
| SphygmoCor | Procedure | — | UNRESOLVED |
| Venous occlusion plethysmography | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Category 1
- description
- Examination of participants prior to chemotherapy. Venous occlusion plethysmography SphygmoCor 24hour blood pressure DEXA scan Laboratory blood samples
- interventionNames
- Procedure: Venous occlusion plethysmography
- Procedure: SphygmoCor
- Procedure: 24hour blood pressure
- Procedure: DEXA scan
- Biological: Laboratory blood samples
- type
- EXPERIMENTAL
- label
- Category 2
- description
- Examination of participants immediately after chemotherapy. Venous occlusion plethysmography SphygmoCor 24hour blood pressure DEXA scan Laboratory blood samples
- interventionNames
- Procedure: Venous occlusion plethysmography
- Procedure: SphygmoCor
- Procedure: 24hour blood pressure
- Procedure: DEXA scan
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 99 Years
Show eligibility criteria text
Inclusion Criteria: * women referred to receive adjuvant chemotherapy for primary operable non-metastatic breast cancer Exclusion Criteria: * former og actual use of cytostatics * pregnancy
References
Publications (1)
- DERIVEDFredslund SO, Gravholt CH, Laursen BE, Jensen AB. Key metabolic parameters change significantly in early breast cancer survivors: an explorative PILOT study. J Transl Med. 2019 Apr 1;17(1):105. doi: 10.1186/s12967-019-1850-2. PMID 30935397